ArticleBiomedical reports2026
ERp46 mitigates lipotoxic ER stress to preserve GLUT2 expression and insulin secretion in β-cells.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipotoxicity-induced β-cell dysfunction is a critical contributor to the pathogenesis of type 2 diabetes mellitus. The aim of the present study was to investigate the role of endoplasmic reticulum-resident protein 46 (ERp46) in regulating glucose transporter 2 (GLUT2) expression and insulin secretion in β-cells under palmitic acid (PA)-induced lipotoxic stress. β-TC6 cells were treated with PA to induce lipotoxicity, and ERp46 expression was silenced using specific small interfering RNA. GLUT2 expression and insulin secretion were assessed, and the involvement of protein kinase B (AKT) signaling was evaluated. The results demonstrated that PA significantly decreased GLUT2 expression and insulin secretion, while ERp46 expression was upregulated as a potential compensatory response. ERp46 knockdown exacerbated the reduction of GLUT2 expression and insulin secretion. Furthermore, PA treatment reduced phosphorylated AKT (p-AKT) levels without altering total AKT expression, and ERp46 knockdown further decreased p-AKT levels. The activation of AKT using AKT activator compound SC79 restored GLUT2 expression and insulin secretion in ERp46-depleted cells. These findings indicated that ERp46 helps preserve β-cell function under lipotoxic stress, potentially by stabilizing ER proteostasis and supporting AKT phosphorylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.